Comparison of Duodenal Stenting and Gastrojejunostomy for Duodenal Obstruction with Biliary Obstruction

J Gastrointest Surg. 2022 Sep;26(9):1853-1862. doi: 10.1007/s11605-022-05353-6. Epub 2022 May 26.

Abstract

Background: The best palliation for double obstruction (duodenal obstruction with biliary obstruction) remains unclear. We aimed to compare outcomes of duodenal stenting (DuS) with gastrojejunostomy (GJ) and identify factors associated with survival time and time to recurrent biliary obstruction (TRBO).

Methods: Patients who underwent DuS or GJ combined with biliary stenting for double obstruction due to unresectable malignancy were retrospectively enrolled.

Results: In total, 111 patients were included; 84 underwent DuS, and 27 underwent GJ. The weighted survival time of the DuS group was significantly shorter than that of the GJ group (86 days vs 134 days, P < 0.01). Although the weighted TRBO was not significantly different between the two groups, when limited to patients with distal duodenal obstruction, the weighted TRBO was significantly longer in the DuS group than in the GJ group (207 days vs. 32 days, P < 0.01). GJ for distal duodenal obstruction was identified as the factor with the highest hazard ratio and was associated with a shorter TRBO (hazard ratio 8.5, P < 0.01).

Conclusions: Regarding survival time, GJ should be considered the primary treatment for patients with double obstruction. However, for patients with distal duodenal obstruction, DuS should be considered because GJ may be a risk factor for a shorter TRBO.

Keywords: Duodenal Obstructions; Duodenal Stenting; Gastrojejunostomy; Obstructive Jaundice; Palliative Treatment.

MeSH terms

  • Cholestasis* / complications
  • Cholestasis* / surgery
  • Duodenal Obstruction* / etiology
  • Duodenal Obstruction* / surgery
  • Gastric Bypass* / adverse effects
  • Humans
  • Palliative Care
  • Retrospective Studies
  • Stents* / adverse effects